Sunshine Biopharma Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Sunshine Biopharma Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $5.08M, a 178.08% increase year-over-year.
- Sunshine Biopharma Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was -$1.00.
- Sunshine Biopharma Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00.
- Sunshine Biopharma Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $1.83M.
- Sunshine Biopharma Inc. stock issued during period, value, new issues for fiscal 2025 was $1.83M, a 78.54% decline from fiscal 2024.
- Sunshine Biopharma Inc. stock issued during period, value, new issues for fiscal 2024 was $8.52M, a 108.41% increase from fiscal 2023.
- Sunshine Biopharma Inc. stock issued during period, value, new issues for fiscal 2023 was $4.09M.
- Sunshine Biopharma Inc. stock issued during period, value, new issues for fiscal 2020 was $50.00K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $5.08M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $1.83M 10-K · filed 2026-04-03 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2025-06-30 | $1.83M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $8.52M 10-K · filed 2026-04-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $8.52M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $8.52M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $8.52M 10-Q · filed 2025-05-15 | $12.61M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $4.09M 10-K · filed 2024-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2023-06-30 | $4.09M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2024-03-28 | |
| 2022-06-30 | $16.75M 10-Q · filed 2023-08-10 | |
| 2020-12-31 | $50.00K 10-K · filed 2022-03-21 | |
| 2019-09-30 | $423.80K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $103.86K 10-Q · filed 2019-08-15 | |
| 2019-03-31 | $47.31K 10-Q · filed 2019-05-20 | |
| 2018-09-30 | $1.22M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $874.89K 10-Q · filed 2019-08-15 | |
| 2018-03-31 | $341.05K 10-Q · filed 2019-05-20 | |
| 2017-12-31 | $63.91K 10-K · filed 2019-04-12 | |
| 2016-12-31 | $104.13K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |